Multiple Sclerosis – Unmet Need – Unmet Need – Relapsing Forms of Multiple Sclerosis (US/EU)
An increasing number of clinically unique immunomodulatory disease-modifying therapies (DMTs) are approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form of MS. Nevertheless, all approved drugs give way to clinical shortcomings in terms of efficacy, safety, tolerability, and/or delivery, creating opportunities for new and improved DMTs, be they next-in-class or pioneering. This content provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals in the management of relapsing forms of MS and the current level of unmet need in this area. We analyze the commercial opportunities and how new / emerging novel and next-generation compounds may capitalize on these opportunities in our conjoint-based Target Product Profile simulator.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for relapsing forms of MS?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for relapsing forms of MS?
- What are the prevailing areas of unmet need and opportunity in relapsing forms of MS?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new drug for relapsing forms of MS?
PRODUCT DESCRIPTION
Unmet need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 63 U.S. and 31 European neurologists fielded in February 2022
Key companies: Novartis, Sanofi Genzyme, Biogen, Merck KGaA, Teva, Roche / Genentech
Key drugs: Gilenya, Aubagio, Tecfidera / dimethyl fumarate, Mavenclad, Copaxone / glatiramer acetate, Tysabri, Ocrevus
Table of contents
- Multiple Sclerosis - Unmet Need - Unmet Need - Relapsing Forms of Multiple Sclerosis (US/EU)
- Unmet Need - Relapsing Forms of MS - TPP Simulator - April 2022
- Executive summary
- Introduction
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed neurologists' prescribing decisions in relapsing forms of MS
- Importance of efficacy attributes to prescribing decisions in relapsing forms of MS: United States
- Importance of efficacy attributes to prescribing decisions in relapsing forms of MS: Europe
- Importance of safety and tolerability attributes to prescribing decisions in relapsing forms of MS: United States
- Importance of safety and tolerability attributes to prescribing decisions in relapsing forms of MS: Europe
- Importance of convenience of administration attributes to prescribing decisions in relapsing forms of MS: United States
- Importance of convenience of administration attributes to prescribing decisions in relapsing forms of MS: Europe
- Importance of nonclinical factors to prescribing decisions in relapsing forms of MS: United States
- Importance of nonclinical factors to prescribing decisions in relapsing forms of MS: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in relapsing forms of MS: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in relapsing forms of MS: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for relapsing forms of MS: United States
- Overall performance of key therapies for relapsing forms of MS: Europe
- Mean overall performance of key therapies for relapsing forms of MS: United States and Europe
- Relative performance of key therapies for relapsing forms of MS across select efficacy attributes: United States
- Relative performance of key therapies for relapsing forms of MS across select efficacy attributes: Europe
- Relative performance of key therapies for relapsing forms of MS across select safety and tolerability attributes: United States
- Relative performance of key therapies for relapsing forms of MS across select safety and tolerability attributes: Europe
- Relative performance of key therapies for relapsing forms of MS across select convenience of administration attributes: United States
- Relative performance of key therapies for relapsing forms of MS across select convenience of administration attributes: Europe
- Relative performance of key therapies for relapsing forms of MS across select nonclinical attributes: United States
- Relative performance of key therapies for relapsing forms of MS across select nonclinical attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in relapsing forms of MS
- Surveyed neurologistsu2019 satisfaction with the performance of key therapies for relapsing forms of MS on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed neurologistsu2019 satisfaction with the performance of key therapies for relapsing forms of MS on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed neurologists' ascribed level of unmet need across key efficacy attributes in relapsing forms of MS: United States
- Surveyed neurologists' ascribed level of unmet need across key efficacy attributes in relapsing forms of MS: Europe
- Surveyed neurologists' ascribed level of unmet need across key safety and tolerability attributes in relapsing forms of MS: United States
- Surveyed neurologists' ascribed level of unmet need across key safety and tolerability attributes in relapsing forms of MS: Europe
- Surveyed neurologists' ascribed level of unmet need across key convenience of administration attributes in relapsing forms of MS: United States
- Surveyed neurologists' ascribed level of unmet need across key convenience of administration attributes in relapsing forms of MS: Europe
- Surveyed neurologists' ascribed level of unmet need across key nonclinical factors in relapsing forms of MS: United States
- Surveyed neurologists' ascribed level of unmet need across key nonclinical factors in relapsing forms of MS: Europe
- Key findings: unmet need in relapsing forms of MS and related indications
- Surveyed neurologists' ascribed level of unmet need in relapsing forms of MS and related indications: United States
- Surveyed neurologists' ascribed level of unmet need in relapsing forms of MS and related indications: Europe
- Opportunity analysis
- Target product profiles
- Appendix
Related Market Assessment Reports
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
